Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05119023 · ClinicalTrials.gov registry record · NA

Determining Learning Ability in People With Aphasia

A NA study, sponsored by MGH Institute of Health Professions.

Completed
Registry status
NA
Development phase
18
Enrollment target

NCT05119023: Completed NA study, sponsored by MGH Institute of Health Professions.

NCT05119023 is a NA study that has completed, run by MGH Institute of Health Professions. The registered enrollment target is 18 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05119023, a NA study, has completed, sponsored by MGH Institute of Health Professions.

COMPLETED
Registry status
NA
Development phase
18 participants
Enrollment target

Study Summary

Aphasia is an impairment in the expression or comprehension of language that results from stroke, traumatic brain injury or progressive neurological disease. Approximately two million people in the United States suffer from aphasia, which has profound impacts on quality of life, the ability to return to work and participation in life activities. Research has shown that speech-language therapy, the treatment for aphasia, can significantly improve people's ability to communicate. However, a major limitation in the field of aphasia rehabilitation is the lack of predictability in patients' response to therapy and the inability to tailor treatment to individuals. Currently, aphasia treatments are selected largely based on patient's language abilities and language deficits with little consideration of learning ability, which this study refers to as learning phenotype. Learning phenotype has been used to inform rehabilitation approaches in other domains but is not currently considered in aphasia. The overarching hypothesis of this work is that poor alignment of learning ability and language therapy limits progress for patients and presents a barrier to individualizing treatment. The objectives of the proposed study are to (1) determine the learning phenotype of individuals with aphasia, and (2) examine how lesion characteristics (size and location of damage to the brain), language ability and cognitive ability relate to learning ability. To accomplish objectives, investigators propose to measure implicit (observational) and explicit (rule-based) learning ability in people with aphasia via computer-based tasks. Regression models will be used to examine brain and behavioral factors that relate to learning ability.

Primary Outcome

For the SRT observational learning task, responses are made via eye gaze into a visual area of interest (AOI). Reaction times (RTs) are recorded as the time between target onset and gaze fixation within the target AOI. A trial is considered incorrect if an eye fixation was made that does not correspond to the target AOI. RTs for correct trials are examined. Outlier RTs three standard deviations above the mean RT of each block are removed. A score of learning is computed by comparing RTs on the l

Interventions

  • OTHER Brain imaging
  • BEHAVIORAL SRT Observational Learning
  • BEHAVIORAL AGL Observational Learning
  • BEHAVIORAL AGL Rule-based Learning
  • BEHAVIORAL Standardized cognitive-linguistic assessment

Trial Details

FieldValue
Enrollment Target 18 participants
Start Date 2022-06-06
Est. Completion 2023-09-01
Phase NA

What the finished NCT05119023 record still lists

NCT05119023 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).

The record links to 0 conditions, and to 5 interventions - of which Brain imaging is the first listed.

NCT05119023 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT05119023 about?

NCT05119023 is a clinical study titled "Determining Learning Ability in People With Aphasia". Aphasia is an impairment in the expression or comprehension of language that results from stroke, traumatic brain injury or progressive neurological disease. Approximately two million people in the United States suffer from aphasia, which has profound impacts on quality of life, the ability to retur...

What is the current status of trial NCT05119023?

This trial is currently completed. It is a NA study. The enrollment target is 18 participants. The study started on 2022-06-06. Estimated completion is 2023-09-01.

What interventions are being tested in trial NCT05119023?

The interventions under investigation include: Brain imaging (OTHER), SRT Observational Learning (BEHAVIORAL), AGL Observational Learning (BEHAVIORAL), AGL Rule-based Learning (BEHAVIORAL), Standardized cognitive-linguistic assessment (BEHAVIORAL).

Who is sponsoring clinical trial NCT05119023?

This trial is sponsored by MGH Institute of Health Professions, which has 16 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT05119023's enrollment target sits among peer trials

18 1863rd of 2000 higher than 130 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01245179 · 18 participants · Phase 1

    Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease

  • NCT01999361 · 18 participants · NA

    Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss

  • NCT02359825 · 18 participants · Phase 1

    Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function

  • NCT02870244 · 18 participants · Phase 1

    Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05119023, the US trial registry maintained by the National Library of Medicine. NCT05119023 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.